The Calpain Hypothesis of Neurodegeneration: Evidence for a Common Cytotoxic Pathway
暂无分享,去创建一个
[1] D. Salmon,et al. Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.
[2] K. Suzuki,et al. Calpain: novel family members, activation, and physiologic function. , 1995, Biological chemistry Hoppe-Seyler.
[3] W. Markesbery,et al. Brain infarction and the clinical expression of Alzheimer disease. , 1997, JAMA.
[4] H. Kawasaki,et al. Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 alpha. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[5] C. Masters,et al. Proteolytic Processing of Alzheimer's Disease βA4 Amyloid Precursor Protein in Human Platelets (*) , 1995, The Journal of Biological Chemistry.
[6] Z. Khachaturian. Calcium Hypothesis of Alzheimer's Disease and Brain Aging a , 1994, Annals of the New York Academy of Sciences.
[7] R. Siman,et al. Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[8] B. Horecker,et al. Effects of a monoclonal anti-calpain antibody on responses of stimulated human neutrophils. Evidence for a role for proteolytically modified protein kinase C. , 1988, The Journal of biological chemistry.
[9] G. Clifton,et al. A calpain inhibitor attenuates cortical cytoskeletal protein loss after experimental traumatic brain injury in the rat , 1997, Neuroscience.
[10] H. Sorimachi,et al. New era of calpain research , 1994, FEBS letters.
[11] R. Nixon,et al. Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease , 1997, Brain Research.
[12] G. Lynch,et al. Brain fodrin: substrate for calpain I, an endogenous calcium-activated protease. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[13] A. Kaszniak,et al. Clinical trial of indomethacin in Alzheimer's disease , 1993, Neurology.
[14] S. Lipton,et al. Excitatory amino acids as a final common pathway for neurologic disorders. , 1994, The New England journal of medicine.
[15] M. Pontecorvo,et al. Selective memory loss following nucleus basalis lesions: Long term behavioral recovery despite persistent cholinergic deficiencies , 1985, Pharmacology Biochemistry and Behavior.
[16] R. Nixon. Calcium‐Activated Neutral Proteinases as Regulators of Cellular Function Implications for Alzheimer's Disease Pathogenesis a , 1989, Annals of the New York Academy of Sciences.
[17] J. Card,et al. Proteolytic processing of beta-amyloid precursor by calpain I , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[18] J. Krieglstein,et al. Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia in vitro and ischemia in vivo , 1993, Brain Research.
[19] R. Mrak,et al. Interleukin‐1 Expression in Different Plaque Types in Alzheimer's Disease: Significance in Plaque Evalution , 1995, Journal of neuropathology and experimental neurology.
[20] R. Hayes,et al. Calpain inhibitors reduce depolarization induced loss of tau protein in primary septo-hippocampal cultures , 1995, Neuroscience Letters.
[21] R. Bartus. Physostigmine and recent memory: effects in young and aged nonhuman primates. , 1979, Science.
[22] P. Emson,et al. Localization of calpain immunoreactivity in senile plaques and in neurones undergoing neurofibrillary degeneration in Alzheimer's disease , 1991, Brain Research.
[23] R. Bartus,et al. Calpain as a novel target for treating acute neurodegenerative disorders. , 1995, Neurological research.
[24] R. Hayes,et al. Neurofilament 68 and neurofilament 200 protein levels decrease after traumatic brain injury. , 1994, Journal of neurotrauma.
[25] E. Hogan,et al. Changes in myelin and axonal proteins in CaCl2-induced myelopathy in rat spinal cord. , 1984, Central nervous system trauma : journal of the American Paralysis Association.
[26] D. Choi,et al. Glutamate neurotoxicity and diseases of the nervous system , 1988, Neuron.
[27] E. Hogan,et al. Calpain secreted by activated human lymphoid cells degrades myelin , 1995, Journal of neuroscience research.
[28] W. Markesbery,et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.
[29] K. Suzuki,et al. Spatial resolution of fodrin proteolysis in postischemic brain. , 1993, The Journal of biological chemistry.
[30] G. Clifton,et al. Cytoskeletal Derangements of Cortical Neuronal Processes Three Hours after Traumatic Brain Injury in Rats: An Immunofluorescence Study , 1996, Journal of neuropathology and experimental neurology.
[31] E. Masliah,et al. Increased immunoreactivity of brain spectrin in Alzheimer disease: a marker for synapse loss? , 1990, Brain Research.
[32] R. Hayes,et al. Microtubule-associated protein 2 levels decrease in hippocampus following traumatic brain injury. , 1992, Journal of neurotrauma.
[33] E. Hogan,et al. Calpain Expression in Lymphoid Cells , 1995, The Journal of Biological Chemistry.
[34] E. Hogan,et al. Role of calpain in spinal cord injury: increased mcalpain immunoreactivity in spinal cord after compression injury in the rat , 1995, Neurochemistry International.
[35] P. Greengard,et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[36] D. Bozyczko‐Coyne,et al. Prolonged Calpain‐mediated Spectrin Breakdown Occurs Regionally Following Experimental Brain Injury in the Rat , 1996, Journal of neuropathology and experimental neurology.
[37] R. Bartus,et al. Postischemic Administration of AK275, a Calpain Inhibitor, Provides Substantial Protection against Focal Ischemic Brain Damage , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[38] R. Nixon,et al. Calcium Influx into Human Neuroblastoma Cells Induces ALZ‐50 Immunoreactivity: Involvement of Calpain‐Mediated Hydrolysis of Protein Kinase C , 1996, Journal of neurochemistry.
[39] G. Lynch,et al. Inhibition of proteolysis protects hippocampal neurons from ischemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[40] T B Shea,et al. Calcium‐Activated Neutral Proteinase (Calpain) System in Aging and Alzheimer's Disease a , 1994, Annals of the New York Academy of Sciences.
[41] M. Ginsberg. Review : Neuroprotection in Brain Ischemia: An Update (Part II , 1995 .
[42] M. Mattson,et al. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[43] J. LaManna,et al. Local Cerebral Glucose Utilization and Cytoskeletal Proteolysis as Indices of Evolving Focal Ischemic Injury in Core and Penumbra , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[44] G. Lynch,et al. The biochemistry of memory: a new and specific hypothesis. , 1984, Science.
[45] B. Siesjö,et al. Calcium Fluxes, Calcium Antagonists, and Calcium-Related Pathology in Brain Ischemia, Hypoglycemia, and Spreading Depression: A Unifying Hypothesis , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[46] KEVIN S. Lee,et al. Neuroprotection With a Calpain Inhibitor in a Model of Focal Cerebral Ischemia , 1994, Stroke.
[47] E. Hirsch,et al. Increased m-calpain expression in the mesencephalon of patients with parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? , 1996, Neuroscience.
[48] J. Olney,et al. Glutamate and the pathophysiology of hypoxic–ischemic brain damage , 1986, Annals of neurology.
[49] G. Lynch,et al. Time-Related Neuronal Changes following Middle Cerebral Artery Occlusion: Implications for Therapeutic Intervention and the Role of Calpain , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[50] K. Suzuki,et al. Calcium activated neutral protease--structure-function relationship and functional implications. , 1990, Cell structure and function.
[51] R. Bartus,et al. Calpain Inhibitor AK295 Protects Neurons From Focal Brain Ischemia: Effects of Postocdusion Intra-arterial Administration , 1994, Stroke.
[52] R. Nixon,et al. Enhancement of Neurite Outgrowth Following Calpain Inhibition Is Mediated by Protein Kinase C , 1995, Journal of neurochemistry.
[53] R. Bartus,et al. The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.
[54] S. Kadoya,et al. Morphometric assessment of drug effects in experimental spinal cord injury. , 1986, Journal of neurosurgery.
[55] G. Lynch,et al. Calmodulin stimulates the degradation of brain spectrin by calpain , 1987, Synapse.
[56] S. Shimohama,et al. Presence of calpain II immunoreactivity in senile plaques in Alzheimer's disease , 1991, Brain Research.
[57] R. Bartus. Drugs to Treat Age‐Related Neurodegenerative Problems The Final Frontier of Medical Science? , 1990, Journal of the American Geriatrics Society.
[58] G. Lynch,et al. Ischemia triggers NMDA receptor-linked cytoskeletal proteolysis in hippocampus , 1989, Brain Research.
[59] D L Price,et al. Alzheimer's disease: a disorder of cortical cholinergic innervation. , 1983, Science.
[60] D. Paty,et al. Urinary myelin basic protein—like material as a correlate of the progression of multiple sclerosis , 1995, Annals of neurology.
[61] F. Schottler,et al. Calcium-activated proteolysis in rat neocortex induced by transient focal ischemia , 1994, Brain Research.
[62] T. Mcintosh. Neurochemical sequelae of traumatic brain injury: therapeutic implications. , 1994, Cerebrovascular and brain metabolism reviews.
[63] G. Lynch,et al. Presence of brain spectrin in dendrites of mammalian brain: Technical factors involved in immunocytochemical detection , 1988, Synapse.
[64] K. Matsushima,et al. Calcium-dependent binding of phosphorylated human pre interleukin 1 alpha to phospholipids. , 1990, Journal of biochemistry.
[65] R. Bartus,et al. Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[66] K. Wang,et al. Calpain inhibition: an overview of its therapeutic potential. , 1994, Trends in pharmacological sciences.
[67] G. Lynch,et al. Temporal ordering of pathogenic events following transient global ischemia , 1998, Brain Research.
[68] R. Nixon,et al. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[69] H. Sorimachi,et al. Calpain: new perspectives in molecular diversity and physiological‐pathological involvement , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[70] K. Blomgren,et al. Calpain and calpastatin in normal and Alzheimer-degenerated human brain tissue , 1990, Neurobiology of Aging.
[71] A. Young,et al. Excitatory amino acids and Alzheimer's disease , 1989, Neurobiology of Aging.
[72] R. Bartus,et al. Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex in the rat , 1983, Pharmacology Biochemistry and Behavior.